Empagliflozin and Kinetics of Renal Glucose Transport in Healthy Individuals and Individuals With Type 2 Diabetes.

ABSTRACT: Renal glucose reabsorption was measured with the stepped hyperglycemic clamp in 15 subjects with type 2 diabetes mellitus (T2DM) and 15 without diabetes after 2 days and after more chronic (14 days) treatment with empagliflozin. Patients with T2DM had significantly greater maximal renal glucose transport (Tm_G) compared with subjects without diabetes at baseline (459 ± 53 vs. 337 ± 25 mg/min; P < 0.05). Empagliflozin treatment for 48 h reduced the Tm_G in both individuals with and without diabetes by 44 ± 7 and 53 ± 6%, respectively (both P < 0.001). Tm_G was further reduced by empagliflozin in both groups on day 14 (by 65 ± 5 and 75 ± 3%, respectively). Empagliflozin reduced the plasma glucose concentration threshold for glucose spillage in the

SUBMITTER: Al-Jobori H 

PROVIDER: S-EPMC7301160 | biostudies-literature | 2017 Jul

REPOSITORIES: biostudies-literature